FDA to Review Roflumilast Foam for Seborrheic Dermatitis ...Middle East

Medscape - News
If approved, the once-daily foam would be the first topical drug with a new mechanism of action for seborrheic dermatitis in more than two decades. Medscape Medical News

Hence then, the article about fda to review roflumilast foam for seborrheic dermatitis was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA to Review Roflumilast Foam for Seborrheic Dermatitis )

Apple Storegoogle play

Last updated :

Also on site :